AbCellera Biologics Inc. Common Shares (ABCL) Stock Price

ABCLStock

$11.80+107.87%52W

Market Cap$3.82B

P/E—

PEG Ratio—

Div yield—

Beta1.57

ABCL Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)233.96%

Price vs S&P 500 (4W)-0.93%

VGM Score51.26

Book Value / Share (Quarterly)$2.92

P/TBV (Annual)1.10x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-46.31%

Cash Flow / Share (Quarterly)$-0.39

Price vs S&P 500 (YTD)257.58%

Net Profit Margin (TTM)-248.83%

EPS (TTM)$-0.54

10-Day Avg Trading Volume5.36M

EPS Excl Extra (TTM)$-0.54

Revenue Growth (5Y)-20.27%

EPS (Annual)$-0.49

ROI (Annual)-15.14%

Net Profit Margin (5Y Avg)-214.23%

Cash / Share (Quarterly)$1.76

Revenue Growth QoQ (YoY)-76.29%

ROA (Last FY)-10.79%

Revenue Growth TTM (YoY)101.28%

EBITD / Share (TTM)$-0.66

ROE (5Y Avg)-3.09%

Operating Margin (TTM)-340.25%

Cash Flow / Share (Annual)$-0.58

P/B Ratio4.27x

P/B Ratio (Quarterly)2.68x

Net Income / Employee (Annual)$-260,500

EV / Revenue (TTM)55.97x

Net Interest Coverage (TTM)79.25x

ROA (TTM)-12.36%

EV / EBITDA (TTM)15.15x

EPS Incl Extra (Annual)$-0.49

Current Ratio (Annual)11.32x

Quick Ratio (Quarterly)12.42x

3-Month Avg Trading Volume6.78M

52-Week Price Return107.87%

EV / Free Cash Flow (Annual)3.61x

Revenue / Employee (TTM)$117,700

Tangible BV / Share (Quarterly)$2.80

P/S Ratio (Annual)50.90x

Asset Turnover (Annual)0.06x

52-Week High$15.02

Operating Margin (5Y Avg)-381.08%

EPS Excl Extra (Annual)$-0.49

CapEx CAGR (5Y)23.81%

Tangible BV CAGR (5Y)5.36%

26-Week Price Return246.45%

Quick Ratio (Annual)11.08x

13-Week Price Return105.84%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)12.77x

Enterprise Value$3.70B

Revenue / Share Growth (5Y)-21.90%

Asset Turnover (TTM)0.05x

Book Value / Share Growth (5Y)0.86%

Revenue / Employee (Annual)$133,700

Pretax Margin (Annual)-236.39%

Cash / Share (Annual)$1.78

3-Month Return Std Dev102.49%

Net Income / Employee (TTM)$-293,000

ROE (Last FY)-15.14%

Net Interest Coverage (Annual)-1402.93x

EPS Basic Excl Extra (Annual)$-0.49

P/FCF (TTM)160.72x

Receivables Turnover (TTM)2.01x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.54

Receivables Turnover (Annual)1.63x

ROI (TTM)-17.49%

P/S Ratio (TTM)57.78x

Pretax Margin (5Y Avg)-256.28%

Revenue / Share (Annual)$0.25

Tangible BV / Share (Annual)$3.09

Price vs S&P 500 (52W)91.84%

Year-to-Date Return270.76%

5-Day Price Return1.08%

EPS Normalized (Annual)$-0.49

ROA (5Y Avg)-2.13%

Net Profit Margin (Annual)-194.88%

Month-to-Date Return-13.09%

Cash Flow / Share (TTM)$-0.34

EBITD / Share (Annual)$-0.65

Operating Margin (Annual)-288.98%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-3.09%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.54

P/TBV (Quarterly)2.79x

P/B Ratio (Annual)1.06x

Pretax Margin (TTM)-297.36%

Book Value / Share (Annual)$3.22

Price vs S&P 500 (13W)103.04%

Beta1.57x

P/FCF (Annual)18.68x

Revenue / Share (TTM)$0.22

ROE (TTM)-17.49%

52-Week Low$2.75

vGradeD

gGradeD

mGradeA

vgmGradeC

ABCL Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 5, 2026	-$0.17	-$0.18	-9.09%(-$0.01)
Q1 2026	May 11, 2026	-$0.20	-$0.14	+29.11%(+$0.06)
Q4 2025	Feb 24, 2026	-$0.18	-$0.03	+83.33%(+$0.15)
Q3 2025	Nov 6, 2025	-$0.16	-$0.19	-17.28%(-$0.03)
Q2 2025	Aug 7, 2025	-$0.16	-$0.12	+26.53%(+$0.04)

ABCL Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.07

4.13

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
ABCLAbCellera Biologics Inc. Common Shares	D	D	A	57.8x	101.3%	—	—	$11.80
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About AbCellera Biologics Inc. Common Shares

AbCellera is an antibody discovery platform that accelerates clinical candidate identification through proprietary hardware, software, and data science. The company partners with biotechnology and pharmaceutical firms to discover optimized antibody therapies faster and more efficiently than conventional discovery methods. AbCellera's integrated platform reduces time to clinic and de-risks development programs for its partners.

ABCL Next Earnings Report

Report dateNov 9, 2026

QuarterQ3 2026

Report timeAMC

EPS estimate-$0.18

Revenue estimate$6.26M

Also reporting on Nov 9, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

ABCL Insider Transactions

BuyAug 24, 2026
HAYDEN MICHAEL REUBEN
Director
Shares: 53,613Value: $570,442
BuyAug 18, 2026
MONTALBANO JOHN S.
Director
Shares: 10,000Value: $110,300
BuyAug 14, 2026
BOOTH ANDREW
Chief Financial Officer
Shares: 37,200Value: $383,904
BuyAug 12, 2026
HAYDEN MICHAEL REUBEN
Director
Shares: 46,387Value: $481,033

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for August 2026

Companies in Related Industries

PRMPerimeter Solutions, Inc.Chemicals
DFTXDefinium Therapeutics, Inc. Common SharesPharmaceutical Preparations
CBTCabot CorporationIndustrial Chemicals
ADPTAdaptive Biotechnologies Corporation Common StockBiological Products
IPARInterparfums, Inc. Common StockCosmetics & Toiletries
AVNTAvient CorporationPlastics & Resins
RLAYRelay Therapeutics, Inc. Common StockBiological Products
TARSTarsus Pharmaceuticals, Inc. Common StockBiological Products

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.1

Buy

Consensus rating

52-Week Range

Low$2.75

High$15.02